Compare MRCY & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MRCY | EWTX |
|---|---|---|
| Founded | 1981 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 4.3B |
| IPO Year | 1997 | 2021 |
| Metric | MRCY | EWTX |
|---|---|---|
| Price | $78.01 | $38.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 13 |
| Target Price | ★ $114.80 | $52.62 |
| AVG Volume (30 Days) | 568.9K | ★ 1.5M |
| Earning Date | 11-03-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.08 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $983,622,000.00 | N/A |
| Revenue This Year | $10.46 | N/A |
| Revenue Next Year | $11.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.85 | N/A |
| 52 Week Low | $65.04 | $14.25 |
| 52 Week High | $128.45 | $48.51 |
| Indicator | MRCY | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 35.02 | 36.31 |
| Support Level | $73.38 | $37.75 |
| Resistance Level | $89.06 | $41.22 |
| Average True Range (ATR) | 2.31 | 1.91 |
| MACD | 0.00 | -0.27 |
| Stochastic Oscillator | 7.71 | 16.04 |
Mercury Systems Inc is a commercial technology company serving the aerospace and defense industry. The company envisions, creates, and delivers secure open architecture solutions powering a broad range of mission-critical applications in challenging and demanding environments. Its Mercury Processing Platform spans the full breadth of signal processing from radio frequency front end to the human-machine interface to convert meaningful data, gathered in remote and hostile environments, into critical decisions. The company manufactures components, products, modules, and subsystems and sells to defense prime contractors, the U.S. government, original equipment manufacturers, and commercial aerospace companies. Geographically, it derives maximum revenue from the United States.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.